<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107340</url>
  </required_header>
  <id_info>
    <org_study_id>P01.004.11</org_study_id>
    <nct_id>NCT01107340</nct_id>
  </id_info>
  <brief_title>AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study</brief_title>
  <official_title>AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medacta International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medacta International SA</source>
  <brief_summary>
    <textblock>
      This is a multicentre post-marketing prospective study to evaluate performance and clinical
      outcomes of AMIIStem primary hip system.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of implant survivorship using Kaplan Meier curve</measure>
    <time_frame>10 years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the patient's physical level of activity using the Oxford Hip Score</measure>
    <time_frame>pre-op, annually post-op up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the improvement in quality of life and joint movement using the EuroQol-5D score</measure>
    <time_frame>pre-op, annually post-op up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of implant survivorship as a measure of safety using Kaplan Meier curve</measure>
    <time_frame>6 months, 3 years, 5 years, 7.5 years, 10 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the clinical outcome following total hip replacement using the Harris Hip Score</measure>
    <time_frame>pre-op, 6 months, 3 years, 5 years, 7.5 years, 10 years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Arthritis</condition>
  <condition>Avascular Necrosis</condition>
  <condition>Fracture of the Femoral Neck or Head</condition>
  <condition>Congenital Hip Dysplasia</condition>
  <arm_group>
    <arm_group_label>AMIStem Hip System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who comply with the protocol and received an AMIStem femoral component.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMIStem Hip System</intervention_name>
    <arm_group_label>AMIStem Hip System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a good candidate for a primary hip arthroplasty using AMIStem Hip System

          -  Patient is willing and able to give informed consent to participate in the follow-up
             program

          -  Patient is suitable for surgery and able to participate in the follow-up program.

          -  Those presenting with disease that meets the indication for use for Medacta implants
             defined in the study (on-label use)

        Exclusion Criteria:

          -  Acute systemic or chronic infection

          -  Skeletal immaturity

          -  Severe muscular, neurological, vascular deficiency or other pathologies of the
             affected limb that may compromise the stability of the implant.

          -  Bone condition that may compromise the stability of the implant.

          -  Patient who are unwilling or unable to give consent, or to comply with the protocol
             and the follow-up program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E Field, PhD FRCS(Orth)</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Orthopaedic Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uniklinik Balgrist</name>
      <address>
        <city>Zurich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Elective Orthopaedic Centre (EOC)</name>
      <address>
        <city>Epsom</city>
        <state>Surrey</state>
        <zip>KT18 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Hip Dislocation</mesh_term>
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

